Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C152539
http://purl.obolibrary.org/obo/NCIT_C152539
|
|---|---|
| Preferred Name | Tefinostat |
| Definitions |
A hydroxamic acid-derived histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Tefinostat inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in chromatin remodeling, inhibition of tumor oncogene transcription, inhibition of tumor cell division, and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins; this agent may specifically target HDACs in cells of the monocyte-macrophage lineage.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A hydroxamic acid-derived histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Tefinostat inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in chromatin remodeling, inhibition of tumor oncogene transcription, inhibition of tumor cell division, and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins; this agent may specifically target HDACs in cells of the monocyte-macrophage lineage. |
|---|---|
| prefLabel | Tefinostat
|
| label | Tefinostat
|
| PDQ_Closed_Trial_Search_ID | 633696
|
| code | C152539
|
| Has_Target | |
| prefixIRI | NCIT:C152539
|
| in_subset | |
| Preferred_Name | Tefinostat
|
| FDA_UNII_Code | ZAU91150SB
|
| Contributing_Source | FDA
|
| Maps_To |
HDAC Inhibitor CHR-2845
Tefinostat
|
| CAS_Registry | 914382-60-8
|
| NCI_Drug_Dictionary_ID | 633696
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 633696
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C2830214
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |